Renal function after percutaneous cryoablation of renal masses

Ajzen, Sérgio Aron

doi:10.1590/0100-3984.2020.53.3e1

Cited by 1 publication

(1 citation statement)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The preservation of renal function was similar for both groups. In our study, there was no alteration in renal function following treatment, as previously described in the literature, similar to partial nephrectomy [23][24][25][26][27]. In line with these findings, our study observed that 19% of our patients required a second CA session to manage residual disease, slightly higher than the 93.4% local recurrence-free survival rate noted by Andrews et al [24].…”

Section: Discussionsupporting

confidence: 91%

Single-Probe Percutaneous Cryoablation with Liquid Nitrogen for the Treatment of T1a Renal Tumors

Moulin,

Kammoun,

Audoual

et al. 2023

Cancers

View full text Add to dashboard Cite

Kidney cancer accounts for 3% of adult malignancies and is increasingly detected through advanced imaging techniques, highlighting the need for effective treatment strategies. This retrospective study assessed the safety and efficacy of a new single-probe percutaneous cryoablation system using liquid nitrogen for treating T1a renal cancers. From May 2019 to May 2022, 25 consecutive patients from two academic hospitals, with a median age of 64.8 years [IQR 59; 75.5], underwent cryoablation for 26 T1a renal tumors. These tumors had a median size of 25.3 mm [20; 30.7] and a median RENAL nephrometry score, indicating tumor complexity, of 7 [5; 9]. No major complications arose, but three non-clinically relevant perirenal hematomas were detected on post-procedure CT scans. With a median follow-up of 795 days [573; 1020], the primary local control rate at one month stood was 80.8% (21 out of 26). The five recurrent lesions, which exhibited a higher renal score (p = 0.016), were treated again using cryoablation, achieving a secondary local control rate of 100%. No patient died, and the disease-free survival rate was 92% (23 out of 25). In conclusion, single-probe percutaneous cryoablation emerges as a promising modality for managing small renal masses. Notably, recurrence rates appear influenced by RENAL nephrometry scores, suggesting a need for further research to refine the technique.

show abstract